WARREN, N.J., Aug. 31, 2018 — Celularity, an allogeneic immuno-oncology and placental cell therapeutics company, today announced it entered into a definitive agreement to acquire CariCord, the family cord blood bank established by the University of Colorado and ClinImmune Labs. Through its exclusive ClinImmune Labs relationship, CariCord is the first, and so far the only family cord blood bank to operate inside a FDA Licensed Laboratory. ClinImmune Labs is an academic component of the School of Medicine at the University of Colorado at Denver and Health Sciences Center. Financial details of the transaction were not disclosed. [Read more…]
FamiCord Acquires the Largest Stem Cell Bank in Portugal for $16.5M
FamiCord announced that it is acquiring Stemlab, positioning it to control the largest cord blood bank in Portugal. To execute the transaction, Polski Bank Komórek Macierzystych S.A. (better known as the Polish Stem Cell Bank or PBKM), a leading company of the global Famicord Group, is acquiring a controlling interest in Stemlab. It will be acquiring 95.6% of the company stock for a purchase price of $16.5M. [Read more…]
Cord Blood Banking – Present and Future Outlook
Cord blood banking is defined as the collection and storage of stem cells present within the umbilical cord blood of a newborn for future medical use. Umbilical cord blood is rich in a type of stem cell known as a hematopoietic stem cell (HSC). A large market for the storage of these cells has come into existence over the past 30 years, with public and private cord blood banks now present in all major healthcare markets worldwide. [Read more…]
Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients
SEATTLE, Aug. 06, 2018 — Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant. Dilanubicel has already received PRIME designation from the European Medicines Agency, and Orphan Drug Designation from the FDA and European Commission. [Read more…]
How the Cord Blood and Tissue Market is Changing
The global cord blood and tissue banking market is consolidating, driven by the emergence of holding companies and aggressive M&A activity. This is creating risks for cord blood market participants, as well as new opportunities.
Serious threats to the industry include:
- Low rates of stored cord blood utilization
- Utilization of bone marrow and peripheral blood stem cells as alternative sources of stem cells for HSCT
- Growing prevalence of haploidentical transplantation
- Expensive transplant procedures, ranging from $200-300K
- Difficulty educating Obstetricians about the future value of cellular therapies
- Low rates of market penetration
- Low rates of cord blood awareness among expectant parents
- 1
- 2
- 3
- …
- 30
- Next Page »
